Supplementary Materials

The PDF file includes:

  • Fig. S1. Replacing tk gene with hCD19t in OV does not significantly affect the infection efficiency or cell killing of MDA-MB-468.
  • Fig. S2. Activation of CD19-CAR T cells against OV19t-infected tumor cells expressing CD19t.
  • Fig. S3. CD19-CAR T cells activate and kill MDA-MB-231 cells infected with OV19t.
  • Fig. S4. OV19t-mediated expression of CD19t in tumor cells promotes tumor cell–targeted cytotoxicity of CD19-CAR T cells in vitro.
  • Fig. S5. OV carrying tk does not induce CD19-CAR T cell activity.
  • Fig. S6. Representative fluorescence-activated cell sorting plots of CD19t+ MDA-MB-468 cells from harvested tumors (related to Fig. 3A).
  • Fig. S7. Murine CD19-CAR T cells.
  • Fig. S8. Specificity of combination therapy in the murine MC38 tumor model.
  • Fig. S9. Assessment of OVm19t tumor selectivity.
  • Fig. S10. Schematic of combination therapy concept using OV to introduce CAR targets to solid tumors.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: